These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19642997)

  • 1. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
    Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
    J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
    Wu L; Li X; Su J; He Q; Zhang X; Chang C; Pu Q
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
    Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
    Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
    Chen C; Xu W; Yang J
    Leuk Lymphoma; 2015 Jan; 56(1):141-6. PubMed ID: 24724783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
    Jin J; Jiang DZ; Mai WY; Meng HT; Qian WB; Tong HY; Huang J; Mao LP; Tong Y; Wang L; Chen ZM; Xu WL
    Leukemia; 2006 Aug; 20(8):1361-7. PubMed ID: 16791270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
    Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
    Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
    Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
    Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
    Gu LF; Zhang WG; Wang FX; Cao XM; Chen YX; He AL; Liu J; Ma XR
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):997-1003. PubMed ID: 21152934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with
    Wang F; Xu W; Liu L; Ren X; Liu P; Zheng L; Zhang H; Zhang S; Xu Y; Guo Z
    Hematology; 2021 Dec; 26(1):1040-1045. PubMed ID: 34895093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
    Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
    Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Liu H; Zhang J; Ren S; Chen M; Liu L; Zhang H
    Leuk Lymphoma; 2017 Nov; 58(11):2758-2761. PubMed ID: 28406352
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
    Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
    Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
    Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
    Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].
    Liu H; Qian WB; Mai WY; Meng HT; Tong HY; Tong Y; Mao LP; Huang J; Wang L; Jiang DZ; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):9-12. PubMed ID: 18512308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
    Duan W; Yang S; Zhao T; Hu L; Qin Y; Jia J; Wang J; Lu S; Jiang H; Zhang X; Xu L; Wang Y; Lai Y; Shi H; Huang X; Jiang Q
    Ann Hematol; 2023 Oct; 102(10):2695-2705. PubMed ID: 37572135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.